LS Investment Advisors LLC Purchases 402 Shares of Illumina, Inc. (ILMN)
LS Investment Advisors LLC raised its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 12.6% in the fourth quarter, HoldingsChannel.com reports. The firm owned 3,580 shares of the life sciences company’s stock after buying an additional 402 shares during the quarter. LS Investment Advisors LLC’s holdings in Illumina were worth $782,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also recently added to or reduced their stakes in the business. Jennison Associates LLC grew its stake in shares of Illumina by 8.8% during the 4th quarter. Jennison Associates LLC now owns 4,412,621 shares of the life sciences company’s stock valued at $964,114,000 after acquiring an additional 355,200 shares during the period. Assenagon Asset Management S.A. grew its stake in shares of Illumina by 371.9% during the 4th quarter. Assenagon Asset Management S.A. now owns 212,160 shares of the life sciences company’s stock valued at $46,355,000 after acquiring an additional 167,206 shares during the period. American Century Companies Inc. grew its stake in shares of Illumina by 27.4% during the 3rd quarter. American Century Companies Inc. now owns 605,149 shares of the life sciences company’s stock valued at $120,546,000 after acquiring an additional 130,038 shares during the period. Parametric Portfolio Associates LLC grew its stake in shares of Illumina by 41.2% during the 3rd quarter. Parametric Portfolio Associates LLC now owns 290,458 shares of the life sciences company’s stock valued at $57,859,000 after acquiring an additional 84,690 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. grew its stake in shares of Illumina by 6,244.3% during the 3rd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 82,603 shares of the life sciences company’s stock valued at $16,455,000 after acquiring an additional 81,301 shares during the period. Institutional investors and hedge funds own 92.04% of the company’s stock.
A number of research analysts recently issued reports on the company. Deutsche Bank set a $275.00 price objective on Illumina and gave the company a “buy” rating in a research note on Tuesday, January 16th. Cowen boosted their price objective on Illumina from $250.00 to $275.00 and gave the company an “outperform” rating in a research note on Monday, January 22nd. Leerink Swann boosted their price objective on Illumina from $250.00 to $276.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Morgan Stanley boosted their price objective on Illumina from $145.00 to $157.00 and gave the company an “underweight” rating in a research note on Wednesday, January 31st. Finally, BTIG Research reiterated a “hold” rating on shares of Illumina in a research note on Tuesday, January 16th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $241.39.
Shares of Illumina, Inc. (NASDAQ:ILMN) opened at $223.11 on Thursday. The stock has a market capitalization of $32,404.68, a P/E ratio of 54.97, a PEG ratio of 2.91 and a beta of 0.92. Illumina, Inc. has a twelve month low of $158.02 and a twelve month high of $248.97. The company has a current ratio of 3.99, a quick ratio of 3.55 and a debt-to-equity ratio of 0.42.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.22 by $0.22. The business had revenue of $778.00 million for the quarter, compared to analysts’ expectations of $752.04 million. Illumina had a return on equity of 21.52% and a net margin of 26.56%. The company’s revenue for the quarter was up 25.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.85 EPS. equities research analysts predict that Illumina, Inc. will post 4.59 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.thecerbatgem.com/2018/02/15/ls-investment-advisors-llc-purchases-402-shares-of-illumina-inc-ilmn.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.